trending Market Intelligence /marketintelligence/en/news-insights/trending/edjdfcndudyf4ymgo4k-0q2 content esgSubNav
In This List

2 Albireo Pharma directors step down; replacements named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


2 Albireo Pharma directors step down; replacements named

Boston-based Albireo Pharma Inc. said June 8 that Julia Brown and Heather Preston resigned from its board of directors.

Albireo added Anne Klibanski and Stephanie Okey to the board to fill the vacated positions.

Klibanski serves as chief academic officer for Partners HealthCare and as academic dean for Partners HealthCare at Harvard Medical School. Okey was most recently senior vice president, head of North America for rare diseases, and U.S. general manager for rare diseases at Sanofi unit Genzyme Corp.

Albireo develops therapies for orphan pediatric liver diseases and gastrointestinal disorders in the U.S.